Literature DB >> 31990371

Higher levels of TNF and IL-4 cytokines and low miR-182 expression in visceral leishmaniasis-HIV co-infected patients.

Walter Lins Barbosa Júnior1, Alda Maria Justo2, Ana Maria Aguiar Dos Santos1, Virginia Maria Barros de Lorena3, Rodrigo Feliciano do Carmo4, Fábio Lopes de Melo1, Zulma Maria de Medeiros1,2, Luydson Richardson Silva Vasconcelos1,2.   

Abstract

AIMS: The aim of the present study was to assess serum cytokine and miRNA expression in visceral leishmaniasis-HIV (VL-HIV) co-infection and HIV mono-infection. METHODS AND
RESULTS: We analysed 113 serum samples from HIV patients in areas endemic for leishmaniasis. The diagnosis of VL was confirmed in 65 of these 113 samples. The VL-HIV and HIV groups presented significant differences regarding haemoglobin level (P < .0001), lymphocyte count (P = .0444), white blood cell count (P = .0108), weight loss (P = .0310), HIV load (P < .0001) and CD4+ T-lymphocytes count (P = .0003). Levels of IL-6 and IL-10, IFN-γ and IL-6, IFN-γ and IL-10, TNF and IL-2 were positively correlated in VL-HIV co-infection, indicating higher serum levels of TNF and IL-4 (P < .0001). In addition, miR-182 expression was found to be significantly higher in HIV (P = .009), miR-210 exhibited no statistically significant difference between groups, and nonexpression of miR-122 was found in both groups.
CONCLUSION: Together, TNF, IL-4 and miR-182 may represent circulatory biomarkers of VL-HIV co-infection.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV/AIDS; cytokine; expression profiling; leishmaniasis

Year:  2020        PMID: 31990371     DOI: 10.1111/pim.12701

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  1 in total

1.  The Comparison of the IFN-ɤ, TNF-α and IL-10 Cytokines in Healing and Non-healing Cutaneous Leishmaniasis.

Authors:  Mina Taraghian; Helena Hanif; Parisa Mousavi; Zahra Baharlooeyan Cheshmeh; Azam Samei; Abbas Abdollahi; Hossein Vazini
Journal:  Iran J Parasitol       Date:  2021 Jul-Sep       Impact factor: 1.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.